Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is ...

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, ...

Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Vertex Pharmaceuticals (NASDAQ ... what they believe are the 10 best stocks to buy right now. Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties ...

Vertex Pharmaceuticals (NASDAQ ... including one approved early this year. CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex ...